It depends on the standard you follow. As of September 2026, Eli Lilly and Company (LLY) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 4.49% / 30% · (Cash+Inv) / Mkt Cap (36m) 0.81% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 4.49% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 0.44% / 33% · Receivables / Mkt Cap (36m) 2.29% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 4.49% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 0.44% / 33.33% · Receivables / Mkt Cap (24m) 2.29% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 36.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 5.08% / 33.33% · Receivables / Avg Assets (4Q) 17.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 33.4% / 33.33% · (Cash+ST Inv) / Total Assets 3.30% / 33.33% · (Cash+Recv) / Total Assets 20.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Eli Lilly and Company (LLY) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Eli Lilly and Company is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Eli Lilly and Company reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Eli Lilly and Company (NYSE: LLY) is a Healthcare company (Drug Manufacturers - General) with a market capitalization of $1.35T. The Maz Rating grades it against the other companies in its sector.
Eli Lilly and Company's current Maz Rating and its five factor grades are for members: log in to see them.
At $1434.26, Eli Lilly and Company trades at 46.4x trailing earnings, 15.6x sales and 31.8x book value, with an EV/EBITDA of 31.1. Over the last twelve months it generated about $86.5B of revenue and $29.1B of net income. It runs a gross margin of 83.6%, an operating margin of 46.1% and a net margin of 31.9%. It shows return on equity of 83.6%, return on invested capital of 30.5% and a free cash flow yield of 1.5%. On the balance sheet: a debt-to-equity ratio of 1.23 and a current ratio of 1.39. Over the past 52 weeks the share price ranged from $850.51 to $1475.25, with a beta of 0.45.
Eli Lilly and Company pays a dividend yielding 0.48%, with 22% of earnings paid out. Its Maz Dividend Score is 4.10 out of 5, ranked against the other dividend payers in its sector (Safety 3.23, Growth 4.97, Yield 1.43, Consistency 4.42).
46 Wall Street analyst ratings cover the stock: 34 Buy, 9 Hold and 3 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.